MATINAS BIOPHARMA HOLDINGS, INC. Research and Development Asset Acquired Other than Through Business Combination, Written-off
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $291.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2024-03-27
- MATINAS BIOPHARMA HOLDINGS, INC. research and development asset acquired other than through business combination, written-off for the quarter ending 2022-12-31 was $0.00.
- MATINAS BIOPHARMA HOLDINGS, INC. research and development asset acquired other than through business combination, written-off for the quarter ending 2022-09-30 was $0.00.
- MATINAS BIOPHARMA HOLDINGS, INC. research and development asset acquired other than through business combination, written-off for the quarter ending 2022-06-30 was $0.00.
- MATINAS BIOPHARMA HOLDINGS, INC. research and development asset acquired other than through business combination, written-off for the quarter ending 2022-03-31 was $291.00K.
- MATINAS BIOPHARMA HOLDINGS, INC. research and development asset acquired other than through business combination, written-off for fiscal 2022 was $291.00K, a 75.75% decline from fiscal 2021.
- MATINAS BIOPHARMA HOLDINGS, INC. research and development asset acquired other than through business combination, written-off for fiscal 2021 was $1.20M.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month as first filed | Research and Development Asset Acquired Other than Through Business Combination, Written-off 6 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 6 month as first filed | Research and Development Asset Acquired Other than Through Business Combination, Written-off 9 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 9 month as first filed | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month |
|---|---|---|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $0.00 derived: sum of 2 quarters · filed 2024-03-27 | $0.00 derived: sum of 3 quarters · filed 2024-03-27 | $291.00K 10-K · filed 2024-03-27 | |||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $0.00 derived: sum of 2 quarters · filed 2023-11-08 | $291.00K 10-Q · filed 2023-11-08 | $291.20K 10-Q · filed 2022-11-02 | $291.00K derived: sum of 4 quarters · filed 2023-11-08 | ||
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $291.00K 10-Q · filed 2023-08-09 | $291.20K 10-Q · filed 2022-08-11 | $291.00K derived: sum of 3 quarters · filed 2023-08-09 | |||
| 2022-03-31 | $291.00K 10-Q · filed 2023-05-10 | $291.20K 10-Q · filed 2022-05-12 | $291.00K derived: sum of 2 quarters · filed 2023-05-10 | ||||
| 2021-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-03-11 | $1.20M 10-K/A · filed 2022-03-11 | |||||
| 2021-09-30 | $1.20M 10-Q · filed 2021-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B |